SEC Filing Summary: Nephros, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nephros, Inc. on June 21, 2006. The report documents events occurring on the same date, specifically the company's Annual Meeting of Stockholders held in New York, New York.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Events
- Annual Meeting: The company held its Annual Meeting of Stockholders on June 21, 2006.
- Management Presentation: President and CEO Norman J. Barta delivered an address accompanied by slides (attached as Exhibit 99.1).
- Regulatory Update: Management disclosed that Nephros filed an Investigational Device Exemption (IDE) application with the FDA earlier in the year for its OLpýr H2H module.
- FDA Interaction: The company received questions from the FDA regarding the IDE application the week prior to the meeting.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or numerical outlooks. The primary operational update concerns the regulatory status of the OLpýr H2H module. The receipt of questions from the FDA represents a standard contingency in the device approval process, though the specific nature of the questions is not detailed in this summary.
Investor Verification Checklist
- Review Exhibit 99.1 for the full text of the CEO's address and strategic slides.
- Monitor future filings for the resolution of FDA questions regarding the OLpýr H2H module IDE application.
- Check subsequent quarterly reports (10-Q) or annual reports (10-K) for financial metrics not included in this 8-K.